

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (original) A method of treating a patient with Pompe's disease, comprising: administering to the patient a therapeutically effective amount of human acid alpha glucosidase.

2-34. (canceled)

35. (new) A method of treating a human patient with infantile Pompe's disease, comprising: administering to the patient at least 10 mg/kg body weight per week of human acid alpha glucosidase, whereby the patient survives to be at least one year old.

36. (new) The method of claim 35, wherein the patient is administered at least 60 mg/kg body weight per week.

37. (new) The method of claim 35, wherein the patient is administered at least 120 mg/kg body weight per week.

38. (new) The method of claims 35, wherein the patient is administered a single dosage of alpha-glucosidase per week.

39. (new) The method of claim 35, wherein the patient is administered three dosages of alpha-glucosidase per week.

40. (new) The method of claim 35, wherein the amount is administered per week for a period of at least 24 weeks.

41. (new) The method of claim 35, wherein the alpha-glucosidase is administered intravenously.

42. (new) The method of claim 35, wherein the alpha-glucosidase was produced in milk of a transgenic mammal.

43. (new) The method of claim 35, wherein the alpha-glucosidase is predominantly in a 110 kD form.

44. (new) The method of claim 35, further comprising monitoring a level of human acid alpha glucosidase in the patient.

45. (new) The method of claim 44, further comprising administering a second dosage of human acid alpha glucosidase if the level of alpha-glucosidase falls below a threshold value in the patient.

46. (new) The method of claim 35, wherein the human alpha glucosidase is administered intravenously and the rate of administration increases during the period of administration.

47. (new) The method of claim 46, wherein the rate of administration increases by at least a factor of ten during the period of administration.

48. (new) The method of claim 46, wherein the rate of administration increases by at least a factor of ten within a period of five hours.

49. (new) The method of claim 46, wherein the patient is administered a series of at least four dosages, each dosage at a higher strength than the previous dosage.

50. (new) The method of claim 49, wherein the dosages are a first dosage of 0.03-3 mg/kg/hr, a second dosage of 0.3-12 mg/kg/hr, a third dosage of 1-30 mg/kg/hr and a fourth dosage of 2-60 mg/kg/hr.

51. (new) The method of claim 50, wherein the dosages are a first dosage of 0.1-1 mg/kg/hr, a second dosage of 1-4 mg/kg/hr, a third dosage of 3-10 mg/kg/hr and a fourth dosage of 6-20 mg/kg/hr.

52. (new) The method of claim 51, wherein the dosages are a first dosage of 0.25-4 mg/kg/hr, a second dosage of 0.9-1.4 mg/kg/hr, a third dosage of 3.6-5.7 mg/kg/hr and a fourth dosage of 7.2-11.3 mg/kg/hr.

53. (new) The method of claim 52, wherein the dosages are a first dosage of 0.3 mg/kg/hr, a second dosage of 1 mg/kg/hr, a third dosage of 4 mg/kg/hr and a fourth dosage of 12 mg/kg/hr.

54. (new) The method of claim 49, wherein the first, second, third and fourth dosages are each administered for periods of 15 min to 8 hours.

55. (new) The method of claim 49, wherein the first, second, third and fourth dosages are administered for periods of 1 hr, 1hr, 0.5 hr and 3 hr respectively.

56. (new) The method of claim 35, wherein the dosage is at least 40 mg/kg body weight per week.

57. (new) The method of claim 35, further comprising detecting a reduction in hypertrophic cardiomyopathy responsive to the administering.

58. (new) The method of claim 35, further comprising detecting increased alpha-glucosidase activity in muscle responsive to the administering.

59. (new) The method of claim 35, wherein the human alpha-glucosidase is administered to a population of patients with infantile Pompe's disease and at least 50% survive more than six months post diagnosis of the infantile Pompe's disease without life-saving intervention.

60. (new) A method of treating a human patient with infantile Pompe's disease, comprising: administering to the patient at least 15 mg/kg body weight per week of human acid alpha-glucosidase.

61. (new) The method of claim 60, wherein the patient is administered at least 20 mg/kg body weight per week of human acid alpha-glucosidase.

62. (new) The method of claim 60, wherein as a result of the treatment method the patient survives to be at least 1 year old.

63. (new) The method of claim 62, wherein the acid alpha-glucosidase is administered intravenously once a week.

64. (new) The method of claim 62, wherein the acid alpha-glucosidase is administered intravenously twice a week.